A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis

Takeshi Tomoda, Hironari Kato, Sho Mizukawa, Shinichiro Muro, Yutaka Akimoto, Daisuke Uchida, Kazuyuki Matsumoto, Naoki Yamamoto, Shigeru Horiguchi, Koichiro Tsutsumi, Hiroyuki Okada

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP.

Original languageEnglish
Pages (from-to)405-408
Number of pages4
JournalActa medica Okayama
Volume70
Issue number5
Publication statusPublished - 2016

Keywords

  • NSAIDs
  • Nitroglycerin
  • Post-ERCP pancreatitis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis'. Together they form a unique fingerprint.

Cite this